Long-term results of phase II ablation after breast lumpectomy added to extend intraoperative margins (ABLATE l) trial.
V Suzanne Klimberg, Daniela Ochoa, Ronda Henry-Tillman...
https://pubmed.ncbi.nlm.nih.gov/24655863/Actively Recruiting
Led by Innoblative Designs, Inc. · Updated on 2026-02-11
10
Participants Needed
1
Research Sites
260 weeks
Total Duration
Researchers are evaluating the safety and clinical accuracy of the SIRA-1000, a radiofrequency ablation RFA electrosurgical device, in patients undergoing breast conserving surgery for breast cancer. The study focuses on using RFA to treat the margins surrounding the tumor site after lumpectomy, aiming to destroy remaining cancer cells in the tissue around the lump. This feasibility study is designed for women diagnosed with specific types of breast cancer, including infiltrating ductal carcinoma with certain hormone receptor statuses and tumor grades. During surgery, after the tumor is removed, the surgeon will place the SIRA-1000 device into the breast cavity and perform the RFA procedure to ablate the tissue margins around the surgical site. The device is secured with a stitch to maintain contact with the tissue. After ablation, tissue samples including the tumor and ablated edges are sent for microscopic examination. The surgery then proceeds as standard, with patient discharge based on routine post-surgical care. Participants will be monitored for safety by tracking adverse events over approximately 12 months, with follow-up extending up to five years. Healing will be assessed using the BREAST-Q Questionnaire at six months. The study involves tissue evaluations and patient-reported outcomes to measure recovery and treatment safety. Overall, the trial spans multiple years of observation to gather comprehensive data on the devices performance and patient healing.
CONDITIONS
Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adjunct to Breast Conserving Surgery
C
Clinical Trials Manager
V
VP Quality Assurance & Regulatory Affairs
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Innoblative Designs, Inc.
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | SIRA-1000 RFA Device + BCS | Standard Breast-Conserving Surgery (Lumpectomy) |
|---|---|---|
| What it is | The SIRA-1000 radiofrequency ablation (RFA) device is used during breast-conserving surgery (BCS) to ablate tissue around the tumor bed. It is designed to provide approximately 1 cm depth of ablation as an adjunct to surgical margin extension. | Standard breast-conserving surgery (lumpectomy) removes the tumor area with a margin of healthy tissue, without adjunct intraoperative ablation. |
| Role in trial | Investigational device tested for feasibility and safety as adjunct to BCS, including intraoperative margin extension. | Not included in this study. Provided as reference for current-care clinical context. |
| Primary use | Used to ablate tissue surrounding the tumor cavity intraoperatively after lumpectomy, aiming to extend surgical margins. | Removes tumor and adjacent tissue via lumpectomy; surgical margins extended by excision alone without ablation. |
| How it is given or performed | The SIRA-1000 device, sized to the post-lumpectomy cavity, delivers radiofrequency energy to ablate tissue surfaces intraoperatively, under surgical and device monitoring. | Tumor-removal and margin excision are performed by standard surgical techniques without intraoperative device ablation. |
| Important limitations | Trial is small (10 participants), single center, and non-randomized; results may not generalize to broader populations or routine practice. Device-specific risks and procedural limits remain to be established. | Although standard lumpectomy is effective for eligible patients, incomplete excision or positive margins may occasionally require reoperation or additional therapy. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Day of surgery
Participants undergo breast conserving surgery. During surgery, the SIRA-1000 radiofrequency ablation device is placed in the breast cavity to treat the margins of the lumpectomy site. Surgery is completed as standard and discharge is determined by the medical team.
1 surgical visit (in-person)
Duration - Up to 12 months with follow-up for 5 years
Participants are monitored for safety and healing after the surgery and device treatment, including assessment of adverse events and healing process using questionnaires.
Regular follow-up visits over 12 months and annual visits up to 5 years
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Have more questions? Get in touch with our team for quick support
V Suzanne Klimberg, Daniela Ochoa, Ronda Henry-Tillman...
https://pubmed.ncbi.nlm.nih.gov/24655863/Innoblative Designs, Inc.
Lead Sponsor